Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study

NCT02614261 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02614261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02614261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Chronic Migraine - the REGAIN Study
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2015
Completion date
July 14, 2021
Enrollment
1,117 (actual)
Sites
117

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine